Share Dilution

SyntheticMR Supplementary General Meeting Announcement

The extraordinary general meeting of SyntheticMR AB (publ) (“SyntheticMR” or the “Company”) was held today on March 29, 2022 and the following resolutions were adopted by the shareholders.

Approval of the resolution of the board of directors of a managed share issue

The Extraordinary General Meeting unanimously decided, in accordance with the Board’s proposal, to approve the Board’s decision to issue a maximum number of 1,250,000 shares with derogation from the preferential right of shareholders at the subscription price of SEK 48 per share.

The reason for waiving the shareholders’ pre-emptive right is to enable the Company to raise capital quickly and efficiently, which in turn provides flexibility for potential short-term investment opportunities, helps reduce exposure to price fluctuations on the capital market as well as the opportunity to benefit from the current interest in the Company’s shares from potential institutional investors. Additional reasons for the discrepancy are that it is seen as positive with increased participation in the Company among institutional investors. An overall assessment and a careful examination have been carried out by the Board of Directors, according to which an issue of new shares with derogation from the shareholders’ preferential right is a more justified alternative for the Company’s shareholders than a capital increase with subscription right and that it is objectively in the best interests of both the Company and its shareholders.

The subscription price has been determined through an accelerated order book process and the Board of Directors therefore believes that the subscription price correctly reflects current market conditions and demand.

By issuing shares, the share capital is increased by SEK27,750.0000 from SEK 896,897.3160 for SEK 924,647.3160. The number of shares and votes is increased by 1,250,000 from 40,400,780 to 41,650,780 shares and votes. For existing shareholders, the dilution amounts to a total of approximately 3% of the number of shares and votes of the Company based on the number of shares and votes after the completion of the share issue. .

For more details regarding the resolutions described above, please refer to the notice and full proposals available on the Company’s website,

For more information, please contact:

Ulrik HarrysonCEO

+46 70 529 29 87

[email protected]

Johanna NorenCFO and Head of Investor Relations

+46 70 619 21 00

[email protected]

On SyntheticMR

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB developed SyMRI®, providing multiple contrast-tunable images and quantitative data from a single 6-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative brain data. SyMRI MSK provides multiple contrast images and quantitative data for MSK anatomy. SyMRI NEURO is CE marked and FDA 510(k) cleared and SyMRI MSK is CE marked. SyMRI is a registered trademark in Europe and the United States. SyntheticMR is listed on the Stock market in Stockholm, Sweden. For more information, visit,c3535219

(c) Decision 2022. All rights reserved., sources Press Releases – English